Eli Lilly Says 'Vitriol' Behind Teva's Bid To Triple IP Verdict
Eli Lilly & Co. has pushed back on rival Teva Pharmaceuticals' request to triple a $176.5 million migraine drug patent infringement verdict, saying Teva's motion resorted to "vitriol" by misconstruing the...To view the full article, register now.
Already a subscriber? Click here to view full article